share_log

Silk Road Medical (NASDAQ:SILK Shareholders Incur Further Losses as Stock Declines 7.5% This Week, Taking Three-year Losses to 66%

Silk Road Medical (NASDAQ:SILK Shareholders Incur Further Losses as Stock Declines 7.5% This Week, Taking Three-year Losses to 66%

絲路醫療(納斯達克股票代碼:SILK)股東蒙受進一步損失,本週股價下跌7.5%,使三年跌幅達到66%
Simply Wall St ·  04/05 21:52

It is a pleasure to report that the Silk Road Medical, Inc (NASDAQ:SILK) is up 49% in the last quarter. Meanwhile over the last three years the stock has dropped hard. Tragically, the share price declined 66% in that time. So it is really good to see an improvement. The rise has some hopeful, but turnarounds are often precarious.

很高興地報告,絲綢之路醫療公司(納斯達克股票代碼:SILK)在上個季度上漲了49%。與此同時,在過去的一段時間裏 多年來,該股一直大幅下跌。不幸的是,當時股價下跌了66%。因此,看到改善真是太好了。上漲帶來了一些希望,但轉機往往不穩定。

Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.

鑑於過去一週對股東來說很艱難,讓我們調查一下基本面,看看我們能學到什麼。

Because Silk Road Medical made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally hope to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

由於絲路醫療在過去十二個月中出現虧損,我們認爲至少目前市場可能更加關注收入和收入增長。當一家公司沒有盈利時,我們通常希望看到良好的收入增長。一些公司願意推遲盈利以更快地增加收入,但在這種情況下,人們希望良好的收入增長來彌補收益不足。

In the last three years, Silk Road Medical saw its revenue grow by 29% per year, compound. That's well above most other pre-profit companies. In contrast, the share price is down 18% compound, over three years - disappointing by most standards. This could mean hype has come out of the stock because the losses are concerning investors. But a share price drop of that magnitude could well signal that the market is overly negative on the stock.

在過去的三年中,絲路醫療的收入每年複合增長29%。這遠高於大多數其他盈利前公司。相比之下,股價在三年內複合下跌了18%,按照大多數標準,這令人失望。這可能意味着股票大肆宣傳,因爲損失與投資者有關。但是,如此大規模的股價下跌很可能表明市場對該股過於消極。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

公司的收入和收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。

earnings-and-revenue-growth
NasdaqGS:SILK Earnings and Revenue Growth April 5th 2024
納斯達克股票代碼:2024年4月5日SILK收益和收入增長

It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. This free report showing analyst forecasts should help you form a view on Silk Road Medical

可能值得注意的是,我們在上個季度看到了大量的內幕買盤,我們認爲這是積極的。另一方面,我們認爲收入和收益趨勢是衡量業務的更有意義的指標。這份顯示分析師預測的免費報告應該可以幫助您對絲綢之路醫療形成看法

A Different Perspective

不同的視角

Investors in Silk Road Medical had a tough year, with a total loss of 57%, against a market gain of about 27%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 9% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Silk Road Medical has 2 warning signs we think you should be aware of.

絲路醫療的投資者經歷了艱難的一年,總虧損了57%,而市場漲幅約爲27%。但是,請記住,即使是最好的股票有時也會在十二個月內表現不如市場。不幸的是,去年的表現可能預示着尚未解決的挑戰,因爲它比過去五年中9%的年化虧損還要糟糕。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,冒險吧——絲路醫療有兩個警告信號,我們認爲你應該注意。

Silk Road Medical is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

絲路醫療並不是內部人士唯一買入的股票。對於那些喜歡尋找獲利投資的人來說,這份最近有內幕收購的成長型公司的免費清單可能就是入場券。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論